$356.59 0.9 0.3%
Last Trade - 22/01/21
Market Cap | £10.06bn |
Enterprise Value | £10.09bn |
Revenue | £555.1m |
Position in Universe | 740th / 6630 |
Industry | Market | |
---|---|---|
|
|
|
|
|
|
|
|
Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
---|---|---|---|---|---|---|---|---|---|---|
452.2 | 499 | 563 | 643 | 714 | 738.7 | 847.6 | 950.5 | +10.3% | ||
+5.2 | -5.0 | -13.6 | +28.4 | -12.3 | +97.4 | +1.68 | +16.9 | |||
x
|
||||||||||
Profitability | ||||||||||
%
|
||||||||||
%
|
||||||||||
%
|
||||||||||
Cashflow | ||||||||||
Dividends | ||||||||||
Balance Sheet | ||||||||||
m
|
||||||||||
m
|
||||||||||
m
|
||||||||||
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing % | |||
Net Gearing % | |||
Cash / Assets % |
Liquidity (ttm) | ||
---|---|---|
Curr. Ratio | ||
Quick Ratio | ||
Interest Cov. |
Efficiency (ttm) | ||
---|---|---|
Asset Turnover | ||
Recs Turnover | ||
Stock Turnover |
Latest interim period vs. prior period | Industry | Market |
---|---|---|
|
|
|
|
|
3yr Compound Annual Growth Rate | Industry | Market |
---|---|---|
|
|
|
|
|
|
|
|
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.
Last Annual | June 30th, 2020 |
Last Interim | September 30th, 2020 |
Incorporated | July 17, 1981 |
Public Since | February 9, 1989 |
No. of Shareholders: | 55,000 |
No. of Employees: | 2,300 |
Sector | Healthcare |
Industry | Biotechnology & Medical Research |
Index | S&P 400 Mid Cap , Nasdaq Composite , S&P Composite 1500 , |
Exchange | NASDAQ Global Select Market |
Shares in Issue | 38,609,307 |
Free Float | (0.0%) |
Eligible for |
ISAs
SIPPs
|
Address | 614 McKinley Pl NE, MINNEAPOLIS, 55413-2610, United States |
Web | https://www.bio-techne.com/ |
Phone | +1 612 3798854 |
Contact | David Clair (IR Contact Officer) |
Auditors | KPMG LLP |
As of 22/01/21, shares in Bio-Techne are trading at $356.59, giving the company a market capitalisation of £10.06bn. This share price information is delayed by 15 minutes.
Shares in Bio-Techne are currently trading at $356.59 and the price has moved by 63.01% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bio-Techne price has moved by 39.42% over the past year.
Of the analysts with advisory recommendations for Bio-Techne, there are there are currently 3 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bio-Techne is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Bio-Techne is scheduled to issue upcoming financial results on the following dates:
The Bio-Techne dividend yield is 0.36% based on the trailing twelve month period.
Last year, Bio-Techne paid a total dividend of 1.28, and it currently has a trailing dividend yield of 0.36%. Looking ahead, Bio-Techne has not announced an ex-dividend date yet.
Bio-Techne has yet to annouce their ex-dividend date. The historic dividend yield on Bio-Techne shares is currently 0.36%.
To buy shares in Bio-Techne you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Bio-Techne are currently trading at $356.59, giving the company a market capitalisation of £10.06bn.
Here are the trading details for Bio-Techne:
Based on an overall assessment of its quality, value and momentum, Bio-Techne is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Bio-Techne are currently priced at $356.59. At that level they are trading at 7.86% premium to the analyst consensus target price of 0.00.
Analysts covering Bio-Techne currently have a consensus Earnings Per Share (EPS) forecast of 5.769 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bio-Techne. Over the past six months, the relative strength of its shares against the market has been 11.01%. At the current price of $356.59, shares in Bio-Techne are trading at 31.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bio-Techne PE ratio based on its reported earnings over the past 12 months is 55.67. The shares are currently trading at $356.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bio-Techne's management team is headed by:
Here are the top five shareholders of Bio-Techne based on the size of their shareholding: